Business Context and Reporting Period
Company: 22nd Century Group, Inc. (NASDAQ: XXII)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: The Company manufactures and distributes combustible tobacco products with reduced nicotine content (RNC), specifically the VLN® brand, which is authorized by the FDA as a Modified Risk Tobacco Product (MRTP). It also operates as a contract manufacturer for third-party tobacco brands. The Company exited its hemp/cannabis business in late 2023, which is reported as discontinued operations.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 (in thousands) | 2024 (in thousands) |
|---|---|---|
| Net Revenues | $17,587 | $24,382 |
| Gross Loss | $(3,137) | $(2,400) |
| Operating Loss | $(11,566) | $(13,950) |
| Net Loss (Continuing Ops) | $(13,117) | $(15,495) |
| Net Loss (Total) | $(5,054) | $(15,164) |
| Cash and Cash Equivalents | $7,149 | $4,422 |
| Working Capital | $10,359 | $1,790 |
| Long-Term Debt | $0 | $5,165 |
Note: Total Net Loss for 2025 includes $8,063 in income from discontinued operations (hemp/cannabis divestiture and insurance settlement).
Material Changes vs. Prior Period
- Revenue Decline: Net revenues decreased 27.9% to $17.6 million, driven by a 56.4% drop in filtered cigar sales due to contract repricing and a shift toward higher-margin cigarette products. Contract manufacturing cigarette revenue also declined slightly.
- Debt Elimination: The Company fully repaid its Senior Secured Credit Facility in September 2025 using proceeds from a Series A Convertible Preferred Stock offering. Long-term debt is now zero.
- Expense Reduction: Total operating expenses decreased 27.0% to $8.4 million, primarily due to reductions in SG&A (legal, consulting, and public company costs) and R&D expenses.
- Discontinued Operations: The Company recognized $8.1 million in income from discontinued operations in 2025, largely due to a $9.5 million insurance settlement regarding a 2022 fire at a former facility and the sale of land assets.
- Liquidity Improvement: Working capital improved significantly from $1.8 million to $10.4 million, and cash balances increased by $2.7 million.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The filing explicitly states there is substantial doubt regarding the Company's ability to continue as a going concern for one year following the report date due to a history of losses and negative cash flows from operations. Management is actively seeking additional funding.
- Regulatory Outlook: The Company is positioned to benefit from the FDA's January 2025 proposed rule mandating reduced nicotine content in cigarettes, as VLN® is the only authorized combustible product meeting this standard. The Company reapplied to the FDA in 2025 to extend its MRTP exposure modification order beyond December 2026.
- Strategic Pivot: In 2025, the Company shifted to a "House of Brands" strategy, creating VLN® versions of popular brands manufactured for existing clients to leverage their distribution channels.
- Unusual Items:
- Deemed Dividends: A $4.7 million deemed dividend was recorded in 2025 due to amendments to the Series A Preferred Stock and warrants, increasing the net loss available to common shareholders.
- Insurance Settlement: A $9.5 million gain was recognized from the settlement of litigation with Dorchester Insurance regarding the Grass Valley facility fire.
- Risks: Key risks include the potential failure to renew FDA MRTP orders, inability to commercialize RNC products profitably, dependence on a small number of contract manufacturing customers, and potential delisting from NASDAQ.
Investor Verification Checklist
- Capital Adequacy: Verify the status of the March 2026 Series B Convertible Preferred Stock offering ($20M total) and whether the remaining $4M tranche was closed to ensure sufficient runway.
- FDA Renewal: Confirm the status of the FDA's decision on the Company's application to extend the VLN® MRTP exposure modification order beyond December 2026.
- Customer Concentration: Review the stability of the top three customers, who accounted for approximately 85% of 2025 revenues.
- Dilution Impact: Assess the dilution impact of outstanding warrants (approx. 5.4 million) and convertible preferred stock, many of which have anti-dilution provisions.
- Revenue Mix: Monitor the transition from low-margin filtered cigars to higher-margin cigarette products and the success of the new "partner VLN" branding strategy.